Gastric cancer treatment: A systematic review

Oncology Reports

Volumn 11, Issue 4, 2004, Pages 911-916

  Berardi, Rossana ^a   Scartozzi, Mario ^a   Romagnoli, Emanuela ^a   Antognoli, Stefania ^a   Cascinu, Stefano ^a  

^a Azienda Ospedaliera Umberto I   (Italy)

Author keywords

Chemotherapy; Gastric cancer; Surgery

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; REVIEW; STOMACH TUMOR;

COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG THERAPY; HUMANS; PALLIATIVE CARE; STOMACH NEOPLASMS;

EID: 16544375854     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.4.911     Document Type: Review

References (56)

1. Karpeh MS, Kelsen DP and Tepper JE: Cancer of the stomach. In: Cancer Principles and Practice of Oncology. De Vita VT, Helman S and Rosemberg SA (eds). Lippincott Williams and Wilkins, Philadelphia, PA, pp 1092-1126, 2001.
2. Kelsen DP: Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 23: 379-389, 1996.
3. Muruyama K, Okabayashi K and Kinoshita T: Progress in gastric cancer surgery in Japan and its limit of radicality. World J Surg 11: 418, 1987.
4. Cuschieri A, Weeden S, Fielding J et al: Patients survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomised clinical trial. Surgical Co-operative Group. Br J Cancer 79: 1522-1530, 1999. (Pubitemid 29116815)
5. Bunt TM, Bonenkamp HJ, Hermans J, et al: Factors influencing non-compliance and contamination in a non-randomized trial of 'western' (R1) versus 'Japanese' (R2) type surgery in gastric cancer. Cancer 73: 1544-1551, 1994. (Pubitemid 24085252)
6. Coombes RC, Schein PS, Chilvers CE, et al: A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 8: 1362-1369, 1990. (Pubitemid 20252308)
7. Lise M, Nitti D, Marchet A, Sahmoud T, et al: Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann Surg Oncol 2: 495-501, 1995.
8. Bajetta E, Buzzoni R, Mariani L, et al: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 13: 299-307, 2002. (Pubitemid 34704984)
9. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M and Teres J: Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 29: 340-342, 1993. (Pubitemid 23025736)
10. Cirera L, Balil A, Batiste-Alentorn E, et al: Randomised clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 17: 3810-3815, 1999.
11. Neri B, Cini G, Andreoli F, et al: Randomised trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 84: 878-880, 2001. (Pubitemid 32385827)
12. Allum WH, Hallissey MT, Ward LC and Hockey MS: A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer 60: 739-744, 1989. (Pubitemid 19275741)
13. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M and Van de Velde CJ: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomised trials. J Clin Oncol 11: 1441-1447, 1993. (Pubitemid 23228247)
14. Pignon JP, Ducreux M and Rougier P: Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 12: 877-878, 1994. (Pubitemid 24110932)
15. Earle CC and Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35: 1059-1064, 1999. (Pubitemid 29339187)
16. Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11: 837-843, 2000.
17. Lowy AM, Mansfield PF, Leach SD, et at Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229: 303-308, 1999.
18. Yano M, Shiozaki H, Inoue M, et al: Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary non-curative gastric cancer. World J Surg 26: 1155-1159, 2002. (Pubitemid 36920275)
19. Melcher AA, Mort D and Maughan TS: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 74: 1651-1654, 1996. (Pubitemid 26386097)
20. Geh JI, Glynne-Jones R, Kwok QS, et al: Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin Oncol (R Coll Radiol) 12: 182-187, 2000. (Pubitemid 30458757)
21. Kelsen D, Karpeh M, Schwartz G, et al: Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14: 1818-1828, 1996. (Pubitemid 26185457)
22. Songun I, Keizer HJ, Hermans J, et al: Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. Eur J Cancer 35: 558-562, 1999. (Pubitemid 29192962)
23. Plukker JT, Mulder NH, Sleijfer DT, et al: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 78: 955-958, 1991.
24. Schuhmacher CP, Fink U, Becker C, et al: Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Cancer 91: 918-927, 2001.
25. Wilke H, Preusser P, Fink U, et al: New developments in the treatment of gastric carcinoma. Semin Oncol 17: S61-S70, 1990.
26. Cascinu S, Labianca R, Graziano F, et al: Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgastrim: a report from the Italian Group for the Study of Digestive Tract cancer (GISCAD). Br J Cancer 78: 390-393, 1998. (Pubitemid 28336429)
27. Ajani JA, Mansfield PF, Lynch PM, et al: Enhanced staging and All chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 17: 2403-2411, 1999. (Pubitemid 29368239)
28. Botet JF, Lightdale CJ, Zauber AG, et al: Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology 181: 426-432, 1991.
29. Sussman H, Halvorsen RA, Illescas FF, et al: Gastric adenocarcinoma: CT versus surgical staging. Radiology 167: 335-340, 1988.
30. Rougier P, Lasser P, Ducreux M, et al: Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 5: 59-68, 1994. (Pubitemid 24094626)
31. Comis S: Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rep 1: 221, 1974.
32. Cocconi G, DeLisi V and DiBlasio B: Randomised comparison of 5-FU alone or combined with mytomicin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66: 1263, 1982.
33. MacDonald JS, Schein PS, Woolley PV, et al: 5-Fluorouracil, mitomycin C and adriamycin (FAM): a new combination chemotherapy program for advanced gastric carcinoma. Ann Intern Med 93: 533-536, 1980.
34. Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Co-operative Group. J Clin Oncol 9: 827-831, 1991.
35. Preusser P, Achterrath W, Wilke H, et al: Chemotherapy of gastric cancer. Cancer Treat Rev 15: 257, 1988.
36. Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993. (Pubitemid 23182046)
37. Pyrhönen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxombicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
38. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997. (Pubitemid 27112884)
39. MacDonald JS: Gastric cancer: chemotherapy of advanced disease. Haematol Oncol 10: 37-42, 1992.
40. Hill ME and Cunningham D: Medical management of advanced gastric cancer. Cancer Treat Rev 4: 113-118, 1998. (Pubitemid 28410090)
41. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al: A phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin-C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993. (Pubitemid 23172955)
42. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, van Cutsem E, et al: Final results of a randomised phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Co-operative Group. J Clin Oncol 18: 2648-2657, 2000. (Pubitemid 30465650)
43. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V, et al: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomised trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12: 2687-2693, 1994. (Pubitemid 24379657)
44. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomised trial. Br J Cancer 80: 269-272, 1999. (Pubitemid 29210117)
45. Kim DY, Kim JH, Lee SH, et al: Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14: 383-387, 2003. (Pubitemid 36367414)
46. Louvet C, Andre T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002. (Pubitemid 35407422)
47. Shimada S, Yagi Y, Kuramoto M, Aoki N and Ogawa M: Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 10: 687-691, 2003.
48. Kruijtzer CM, Boot H, Beijnen JH, et al: Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol 14: 197-204, 2003. (Pubitemid 36305429)
49. Kornek GV, Raderer M, Schull B, et al: Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 86: 1858-1863, 2002.
50. Cascinu S, Graziano F, Barni S, et al: A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian Group for the Study of Digestive Tract Cancer. Br J Cancer 84: 470-474, 2001. (Pubitemid 32215871)
51. Yamada Y, Shirao K, Ohtsu A, et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12: 1133-1137, 2001. (Pubitemid 32834495)
52. Ross JS and McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19: 554-568, 2001. (Pubitemid 32619394)
53. Sakamoto J, Teramukai S, Nakazato H, et al: Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomised controlled clinical trials. J Immunother 25: 405-412, 2002.
54. Heideman DA, van Beusechem VW, Offerhaus GJ, et al: Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism. Hum Gene Ther 13: 1677-1685, 2002. (Pubitemid 35191744)
55. Heideman DA, Snijders PJ, Craanen ME, et al: Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 8: 342-351, 2001. (Pubitemid 32691124)
56. Bramhal SR, Hallissey MT, Whiting J, et al: Marimastat as maintainance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870, 2002.